Table 2.
Cytogenetic fibroblast analysis in the prospective and the retrospective study group
| Study group | Prospective | Retrospective | ||||
|---|---|---|---|---|---|---|
| before SCT (0 mo) | 3 months after SCT | p-value (0 vs 3 mo) | 12 months after SCT | p-value (0 vs 12 mo) | ||
| pat., n | 18 | 13 | 11 | 17 | ||
| pat. with aberrant metaphases, n (%) | 2 (11 %) | 12 (92 %) | 0.002 (McNemar) | 11 (100 %) | 0.002 (McNemar) | 17 (100 %) |
| aberrant metaphases/30 metaphases (%)1 | 13 %; 27 %2 | 77 % (0-100 %) | 0.002 (Wilcoxon) | 63 % (33-97 %) | 0.003 (Wilcoxon) | 83 % (33-100 %) |
| mean no. of breakpoints/aberrant metaphase1 | 2.3; 22 | 3.5 (2.3-6.8) | NA | 2.9 (1.6-5.8) | NA | 3.8 (1.8-5.4) |
Legend to Table 2: pat. = patients. no. = number. 1 Results are given in median and range. 2 Because only two patients had cytogenetic aberrations before SCT, median and range could not be given and only numbers of these two patients are shown. NA = not applicable because of small number of statistical events